Results for tag: "Jakafi"

Jakafi (ruxolitinib) is a hematological drug used to treat myelofibrosis and polycythemia vera, two rare bone marrow diseases. It is a Janus kinase (JAK) inhibitor, which works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Jakafi is the first and only FDA-approved JAK inhibitor for the treatment of these diseases. It is available in both oral and intravenous forms. Jakafi is a relatively new drug, having been approved by the FDA in 2011. Since then, it has become a popular treatment option for patients with myelofibrosis and polycythemia vera. It has been shown to reduce symptoms, improve quality of life, and even prolong survival in some cases. The Jakafi market is highly competitive, with several companies offering their own versions of the drug. These include Incyte Corporation, Novartis, and Pfizer. Other companies, such as Celgene and Gilead Sciences, are also developing their own JAK inhibitors for the treatment of these diseases. Show Less Read more